

# NEXAVAR (sorafenib)

### **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

Age 18 years of age or older

### **Diagnoses**

Patients must have **ONE** of the following:

- 1. Advanced renal cell carcinoma (RCC)
- 2. Unresectable hepatocellular carcinoma (HCC)
- 3. Differentiated thyroid carcinoma (DTC)
  - a. Locally recurrent or metastatic
  - b. Refractory to radioactive iodine treatment
- 4. Osteosarcoma
- 5. Angiosarcoma
- 6. Desmoid Tumors / Aggressive Fibromatosis
- 7. Gastrointestinal Stromal Tumor (GIST)
  - a. Prior therapy with imatinib, sunitinib or regorafenib

#### AND ALL of the following:

- 1. Absence of significant or unstable cardiac disease
- 2. Monitor electrolytes and electrocardiograms on regular basis

## **Prior - Approval Limits**

Quantity 200

200 mg tablets

360 tablets per 90 days

**Duration** 12 months

\_\_\_\_\_

## Prior – Approval Renewal Requirements

Age 18 years of age or older

**Diagnoses** 



# NEXAVAR (sorafenib)

#### Patients must have **ONE** of the following:

- 1. Advanced renal cell carcinoma (RCC)
- 2. Unresectable hepatocellular carcinoma (HCC)
- 3. Differentiated Thyroid carcinoma (DTC)
- 4. Osteosarcoma
- 5. Angiosarcoma
- 6. Desmoid Tumors / Aggressive Fibromatosis
- 7. Gastrointestinal Stromal Tumor (GIST)

#### **AND ALL** of the following:

- 1. Absence of significant or unstable cardiac disease
- 2. Monitor electrolytes and electrocardiograms on regular basis
- 3. NO disease progression or unacceptable toxicity

## Prior - Approval Renewal Limits

Same as above